Beijing Foyou Pharma (601089.SH): Carbazochromium ointment obtained drug registration certificate.

16:42 30/03/2026

Fuyuan Pharmaceuticals (601089.SH) announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd. (referred to as "Anhui Fuyuan"), recently received the Drug Registration Certificate for Ketoconazole Solution for External Use [Specification: 0.005% (30ml: 1.50mg)] issued by the National Medical Products Administration (certificate number: 2026S00816), approving the production of the drug. This drug is used for scalp dandruff disease.

Beijing Foyou Pharma (601089.SH) announced that its wholly-owned subsidiary Anhui Fuyuan Pharmaceutical Co., Ltd. (referred to as "Anhui Fuyuan") recently received the Drug Registration Certificate for Ketoconazole Cream [specification: 0.005% (30ml: 1.50mg)] issued by the National Medical Products Administration (Certificate No.: 2026S00816), approving the production of the drug. This drug is suitable for the treatment of scalp dandruff.

LAPCO Holdings (08472) issues profit warning, expecting a comprehensive net loss of approximately HK$8.4 million to HK$9.3 million for 2025, a reversal from profit to loss year-on-year.

XUANZHUBIO-B (02575) released its annual performance result, with a revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%.

Blue Moon Group (06993) spent 1.0302 million Hong Kong dollars on repurchasing 372,000 shares on March 30th.

LAPCO Holdings (08472) issues profit warning, expecting a comprehensive net loss of approximately HK$8.4 million to HK$9.3 million for 2025, a reversal from profit to loss year-on-year.

XUANZHUBIO-B (02575) released its annual performance result, with a revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%.

Blue Moon Group (06993) spent 1.0302 million Hong Kong dollars on repurchasing 372,000 shares on March 30th.